Fig. 1 | Leukemia

Fig. 1

From: Integrated nuclear proteomics and transcriptomics identifies S100A4 as a therapeutic target in acute myeloid leukemia

Fig. 1

Characterization and quality control of human CD34+ cells and patient AML blast samples. a Example bivariate flow cytometric plot showing viability and immunophenotype of AML blasts used in the study (left). FAB subtype (established by morphology) was confirmed by absence of CD14/CD15 expression [20]. Data exemplifying the purity of CD34+ cells is shown in the right panel. Quadrants delimit background isotype staining. b Example chromatograms of micro-capillary electrophoresis using Agilent 2100 Bioanalyzer from representative RNA samples of AML patients. c Examples of fractionated protein purity and quality. Left panel shows nitrocellulose immunoblots of samples fractioned for nuclear (N), or cytoplasmic (C) proteins. Purity of the fractioned samples was assessed by immunoblotting for GAPDH and histone protein expression. Right panel shows overall protein profile and integrity quality determined through Coomassie Brilliant Blue G staining of polyacrylamide gels

Back to article page